Screener / SEC EDGAR /CIK 0001651308 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

BeOne Medicines Ltd. ONC

Compare with peers Embed
Planned sales, announced before they happen

4 trading plans running, 45 Form 144 notices for $401.4M

10-Q, 10-K and Form 144
Plans running now 4 Dr. Xiaodong Wang, Chan Lee, John V. Oyler, Dr. Xiaobin Wu
Plans adopted 18 reported since May 4, 2023 Form 144 notices 45 $401.4M the sellers expected to sell

What ONC's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From May 22, 2024 to Sep 8, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Xiaobin Wu
President and Chief Operating Officer
Ended 10b5-1 plan Sep 15, 2026 10-Q Nov 5, 2026
Dr. Xiaodong Wang
Co-Founder and Director
Adopted 10b5-1 plan Jun 9, 2026 10-Q Aug 5, 2026
Chan Lee
Senior Vice President, General Counsel
Adopted 10b5-1 plan May 29, 2026 10-Q Aug 5, 2026
John V. Oyler
Co-Founder, Chief Executive Officer, and Chairman of the Board of Directors
Adopted 10b5-1 plan Mar 10, 2026 10-Q May 6, 2026
Dr. Xiaobin Wu
President, Chief Operating Officer
Adopted 10b5-1 plan Nov 7, 2025 10-K Feb 26, 2026
Chan Lee
Senior Vice President, General Counsel
Adopted 10b5-1 plan May 14, 2025 10-Q Aug 6, 2025
Dr. Xiaobin Wu
President, Chief Operating Officer
Adopted 10b5-1 plan May 14, 2025 10-Q Aug 6, 2025
John V. Oyler
Co-Founder, Chief Executive Officer, and Chairman of the Board of Directors
Adopted 10b5-1 plan Mar 12, 2025 10-Q May 7, 2025
Julia Wang
Former Chief Financial Officer
Ended 10b5-1 plan Sep 3, 2024 10-Q Nov 12, 2024
Dr. Xiaodong Wang
Co-Founder and Director
Adopted 10b5-1 plan Aug 12, 2024 10-Q Nov 12, 2024
Dr. Lai Wang
Global Head of R&D
Adopted 10b5-1 plan Jun 13, 2024 10-Q Aug 7, 2024
Julia Wang
Former Chief Financial Officer
Adopted 10b5-1 plan May 22, 2024 10-Q Aug 7, 2024
Dr. Xiaobin Wu
President, Chief Operating Officer
Adopted 10b5-1 plan May 13, 2024 10-Q Aug 7, 2024
John V. Oyler
Chief Executive Officer and Chairman
Adopted 10b5-1 plan Dec 12, 2023 10-K Feb 26, 2024
Julia Wang
Chief Financial Officer
Adopted other arrangement Dec 8, 2023 10-K Feb 26, 2024
Lai Wang
Global Head of R&D
Adopted other arrangement Dec 8, 2023 10-K Feb 26, 2024
Chan Lee
Senior Vice President, General Counsel
Adopted other arrangement Nov 28, 2023 10-K Feb 26, 2024
Xiaobin Wu
President, Chief Operating Officer and General Manager of China
Adopted 10b5-1 plan Nov 22, 2023 10-K Feb 26, 2024
Chan Lee
Senior Vice President
Adopted plan May 9, 2023 10-Q Aug 2, 2023
Chan Lee
Senior Vice President, General Counsel
Adopted 10b5-1 plan – 10-Q May 8, 2024
What the company wrote
Name ( Title ) Action Taken ( Date of Action ) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities Chan Lee (Senior Vice President, General Counsel) Modification ( February 28, 2024 ) Rule 10b5-1 trading arrangement Sale May 30, 2025 1,440 ADSs plus an additional number of ADSs subject to RSUs equal to the net number of shares resulting from applicable RSU vestings after sell-to-cover for withholding tax.
Show the other 12 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 17 filings checked since May 4, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 6, 2026 TITUS BENJAMIN BALL
Officer
1,559 $632K
Nov 5, 2026 CHAN LEE
Officer
1,115 $421K
Sep 30, 2026 CHAN LEE
Officer
1,115 $407K
Sep 8, 2026 XIAODONG WANG
Director, Chair, Scientific Advisory Brd
131,370 $47.1M
Sep 1, 2026 TITUS BENJAMIN BALL
Officer
132 $47K
Aug 25, 2026 XIAOBIN WU
Officer
15,000 $5.6M
Aug 25, 2026 CORAZON D. SANDERS
Former Director
2,075 $788K
Aug 11, 2026 CHAN LEE
Officer
2,002 $719K
Aug 10, 2026 JOHN V OYLER
Director, Officer
240,810 $83.9M
Aug 3, 2026 AARON ROSENBERG
Officer
1,157 $362K
Jul 30, 2026 CHAN LEE
Officer
1,044 $338K
Jul 22, 2026 CHAN LEE
Officer
2,001 $638K
Jul 14, 2026 JOHN V OYLER
Director, Officer
513,574 $156.1M
Jul 10, 2026 JOHN V OYLER
Director, Officer
150,000 $45.4M
Jul 10, 2026 PAN-OYLER FOUNDATION
Director, Officer
49,541 $15.0M
Jun 23, 2026 LAI WANG
Officer
1,068 $296K
Jun 23, 2026 XIAOBIN WU
Officer
1,292 $357K
Jun 23, 2026 JOHN OYLER
Officer, Director
3,410 $934K
Jun 16, 2026 CHAN LEE
Officer
590 $157K
Jun 16, 2026 LAI WANG
Officer
1,169 $310K
Jun 16, 2026 XIAOBIN WU
Officer
1,357 $362K
Jun 16, 2026 JOHN OYLER
Officer, Director
3,693 $981K
Jun 15, 2026 CORAZON D. SANDERS
Director
945 $251K
Jun 11, 2026 XIAOBIN WU
Officer
626 $164K
Jun 11, 2026 LAI WANG
Officer
756 $198K
Jun 11, 2026 AARON ROSENBERG
Officer
631 $163K
Jun 11, 2026 TITUS BENJAMIN BALL
Officer
169 $43K
Jun 11, 2026 CHAN LEE
Officer
428 $110K
Jun 11, 2026 JOHN OYLER
Officer, Director
1,949 $501K
Jun 8, 2026 TITUS BENJAMIN BALL
Officer
136 $37K
Jun 8, 2026 CHAN LEE
Officer
871 $236K
Jun 8, 2026 LAI WANG
Officer
1,367 $368K
Jun 8, 2026 XIAOBIN WU
Officer
1,484 $400K
Jun 8, 2026 JOHN OYLER
Officer, Director
4,940 $1.3M
Jun 1, 2026 QINGQING YI
Director
235 $66K
May 22, 2026 MICHAEL GOLLER
Director
211 $65K
May 22, 2026 RANJEEV KRISHANA
Director
212 $66K
May 22, 2026 ALESSANDRO RIVA
Director
212 $66K
May 22, 2026 MARGARET DUGAN
Director
212 $66K
May 22, 2026 CORAZON D. SANDERS
Director
212 $66K
May 13, 2026 CHAN LEE
Officer
1,328 $418K
Feb 4, 2026 CHAN LEE
Officer
4,676 $1.6M
Dec 15, 2025 JOHN V OYLER
Director, Officer
100,000 $31.9M
Nov 26, 2025 CORAZON D. SANDERS
Director
2,627 $896K
Nov 17, 2025 XIAOBIN WU
Officer
3,991 $1.5M
Show the other 37 notices

From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.